4 NHS considerations

System impact

4.1 There is evidence to suggest that SeQuent Please balloon catheter reduces the incidence of restenosis and therefore the costs associated with subsequent re-intervention for coronary stenoses, and the costs of more prolonged clopidogrel therapy compared with paclitaxel-eluting stent. The most significant savings to the NHS are likely to be associated with a reduction in re-intervention compared with paclitaxel-eluting stent.

4.2 The Committee was advised that if re-intervention is required for subsequent in-stent restenosis, there would be a wider range of options available after treatment with SeQuent Please balloon catheter than after stenting, because of the absence of an additional metallic scaffold.

Committee considerations

4.3 The Committee considered that reductions in restenosis requiring medical treatment, readmission and re-intervention would have long-term cost savings if these reductions were maintained. The anticipated savings would only be realised if the beneficial results of SeQuent Please balloon catheter shown in the studies were maintained beyond the current 1-year follow-up intervals, and the Committee saw no reason to believe that this would not be the case.

  • National Institute for Health and Care Excellence (NICE)